These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1041 related items for PubMed ID: 21353107
1. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107 [Abstract] [Full Text] [Related]
2. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369 [Abstract] [Full Text] [Related]
3. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. N Engl J Med; 2005 Dec 08; 353(23):2450-61. PubMed ID: 16339094 [Abstract] [Full Text] [Related]
4. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. J Rheumatol; 2009 Jun 08; 36(6):1273-82. PubMed ID: 19286847 [Abstract] [Full Text] [Related]
5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S13-8. PubMed ID: 21654265 [Abstract] [Full Text] [Related]
6. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL. Arthritis Care Res (Hoboken); 2012 Feb 08; 64(2):256-61. PubMed ID: 22052584 [Abstract] [Full Text] [Related]
7. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Becker MA, MacDonald PA, Hunt B, Gunawardhana L. Nucleosides Nucleotides Nucleic Acids; 2011 Dec 08; 30(12):1011-7. PubMed ID: 22132950 [Abstract] [Full Text] [Related]
8. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Latourte A, Bardin T, Richette P. Rheumatology (Oxford); 2014 Nov 08; 53(11):1920-6. PubMed ID: 24758886 [Abstract] [Full Text] [Related]
9. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C. Int J Rheum Dis; 2014 Jul 08; 17(6):679-86. PubMed ID: 24467549 [Abstract] [Full Text] [Related]
11. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Schumacher HR, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, Yancopoulos GD, Wang J, Terkeltaub R. Arthritis Care Res (Hoboken); 2012 Oct 08; 64(10):1462-70. PubMed ID: 22549879 [Abstract] [Full Text] [Related]
12. Febuxostat: a new treatment for hyperuricaemia in gout. Edwards NL. Rheumatology (Oxford); 2009 May 08; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778 [Abstract] [Full Text] [Related]
15. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S44-9. PubMed ID: 21654269 [Abstract] [Full Text] [Related]
16. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N, Kumar S, Stamp L, Gow P. J Rheumatol; 2006 Aug 08; 33(8):1646-50. PubMed ID: 16783857 [Abstract] [Full Text] [Related]
17. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P. Postgrad Med; 2014 Mar 08; 126(2):65-75. PubMed ID: 24685969 [Abstract] [Full Text] [Related]
18. Febuxostat--treatment for hyperuricemia and gout? Moreland LW. N Engl J Med; 2005 Dec 08; 353(23):2505-7. PubMed ID: 16339099 [No Abstract] [Full Text] [Related]
19. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Bakris GL, Doghramji PP, Keenan RT, Silber SH. Am J Med; 2014 Jan 08; 127(1):S1. PubMed ID: 24268074 [Abstract] [Full Text] [Related]
20. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y. J Clin Rheumatol; 2011 Jun 08; 17(4 Suppl 2):S35-43. PubMed ID: 21654268 [Abstract] [Full Text] [Related] Page: [Next] [New Search]